The UK Medicines and Healthcare products Regulatory Agency (MHRA) published a safety notice concerning Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30.
The notice describes the affected product or device and the risk identified by the regulator. Healthcare organisations should review the official notice and follow its instructions for identification, quarantine, recall or clinical management where applicable.
This report summarises the regulator's published information. It does not add independent medical advice; clinicians should use the official MHRA notice and local procedures.
